Photo by dronespaul from unsplash
CC‐292 is a potent, selective, orally administered small molecule inhibitor of bruton tyrosine kinase (BTK). The aim of this study was to evaluate the relative bioavailability of newly developed CC‐292… Click to show full abstract
CC‐292 is a potent, selective, orally administered small molecule inhibitor of bruton tyrosine kinase (BTK). The aim of this study was to evaluate the relative bioavailability of newly developed CC‐292 tablet formulation (P22 tablet (P22‐TAB) and CC‐292 capsule formulation (P22 capsule [P22‐CAP]) compared to the current CC‐292 capsule formulation (P1 capsule [P01‐CAP]).
Keywords:
292 potent;
bruton tyrosine;
relative bioavailability;
inhibitor bruton;
tyrosine kinase
Journal Title: Journal of Clinical Pharmacy and Therapeutics
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Journal of Clinical Pharmacy and Therapeutics
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!